newdrugapprovals.org Report : Visit Site

Technical data of the newdrugapprovals.org

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host newdrugapprovals.org. Currently, hosted in United States and its service provider is Automattic Inc .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

new drug approvals all about drugs, live, by dr anthony melvin crasto, worlddrugtracker, open superstar helping millions, 9 million hits on google, pushing boundaries,2.5 lakh plus connections worldwide, 20 lakh plus views on this blog in 218 countries, 7 continents the views expressed are my personal and in no-way suggest the views of the professional body or the company that i represent, use ctrl and+ key to enlarge blog view……………………a 90 % paralysed man in action for you, i am suffering from transverse mylitis and bound to a wheel chair, with death on the horizon, i have lot to acheive search search twitter flickr facebook linkedin youtube new drug approvals advertisements search this blog search search follow new drug approvals on wordpress.com drug approvals by dr anthony melvin crasto meta register log in entries rss comments rss wordpress.com pages about me all about drugs bioavailability clinical trials combinatorial chemistry in drug design disclaimer drug basics drug companies drug design drug discovery drug information drug news drug portals drug resistance drug sites drug synthesis drugs nda drugs, fda2012 fda -us gmp health canada help me/ accolades hsa singapore inda mhlw japan, 厚生労働省 patent expiry dates 1/3 patent expiry dates 2/3 patent expiry dates 3/3 patent portals polymorphism regulations and guidance scientificupdate (uk) on a roll sfda china south africa, mcc special drugs traditional medicine what is a drug world drug tracker archives august 2018 july 2018 june 2018 may 2018 april 2018 march 2018 february 2018 january 2018 december 2017 november 2017 october 2017 september 2017 august 2017 july 2017 june 2017 may 2017 april 2017 march 2017 february 2017 january 2017 december 2016 november 2016 october 2016 september 2016 august 2016 july 2016 june 2016 may 2016 april 2016 march 2016 february 2016 january 2016 december 2015 november 2015 october 2015 september 2015 august 2015 july 2015 june 2015 may 2015 april 2015 march 2015 february 2015 january 2015 december 2014 november 2014 october 2014 september 2014 august 2014 july 2014 june 2014 may 2014 april 2014 march 2014 february 2014 january 2014 december 2013 november 2013 october 2013 september 2013 august 2013 july 2013 june 2013 may 2013 april 2013 march 2013 february 2013 categories 0rphan drug status african medicine aids analytical anda anthony crasto antibodies antimalarials arab medicine australia award ayurveda biosimilar drugs bla blogs breakthrough therapy designation canada cancer cfda china pipeline chinese herbs clinical trials companies conference contrast agent crl dengue diabetes dndi drug discovery drug marketing drug review ema eu 2003 eu 2005 eu 2014 eu 2015 eu 2016 eu 2017 eu 2018 eu pipeline eu submission extended use fast track fda fda 15 fda 2010 fda 2011 fda 2012 fda 2013 fda 2014 fda 2015 fda 2016 fda 2017 fda 2018 featured product flow synthesis formulation generating antibiotic incentives now generic drug generics glenmark glenmark gmp greek medicine herbals homeopathy human medicines european public assessment report epar implants ind 2018 ind filed investigational device exemption (ide) approval japan 2013 japan 2015 japan 2017 japan 2018 japan marketing japan pipeline korea korea 2016 maa malaria manufacturing market info marketing authorisation application eu medical device monoclonal antibody nanotechnology nce nda nda japan neutraceuticals new drug application resubmission fda new drugs new drugs canada new drugs china new drugs eu new drugs japan new use drugs newzealand nice nucleotides organic chemistry patent patents peptide drugs pfizer phase 1 phase1 phase2 drugs phase3 drugs polymorph preclinical china preclinical drugs premture ejaculation priority review process promising clips qbd qidp radiolabelled rare disease regenerative medicine regulatory resubmission fda review scottish medicines consortium sex arousal sfda fast track singapore snda snda japan spectroscopy spotlight stem cells synthesis toxins translational medicine transverse myletis uk unani medicine uncategorized us herbs usfda submission vaccine veterinary vitamins flags and hits join me on linkedin join me on researchgate join me on facebook facebook ...................................................................join me on twitter ..................................................................join me on google plus googleplus myself dr anthony melvin crasto ph.d ( ict, mumbai) , india 29yrs exp. in the feld of organic chemistry,working for glenmark pharma at navi mumbai, india. serving chemists around the world. helping them with websites on chemistry.million hits on google, no advertisements , academic , non commercial site, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution, [email protected]..........+91 9323115463, skype amcrasto64 follow blog via email enter your email address to follow this blog and receive notifications of new posts by email. join 2,246 other followers dr anthony melvin crasto ph.d dr anthony melvin crasto, born in mumbai in 1964 and graduated from mumbai university, completed his ph.d from ict, 1991,matunga, mumbai, india, in organic chemistry, the thesis topic was synthesis of novel pyrethroid analogues, currently he is working with glenmark pharmaceuticals ltd, research centre as principal scientist, process research (bulk actives) at mahape, navi mumbai, india. total industry exp 30 plus yrs, prior to joining glenmark, he has worked with major multinationals like hoechst marion roussel, now sanofi, searle india ltd, now rpg lifesciences, etc. he has worked with notable scientists like dr k nagarajan, dr ralph stapel, prof s seshadri, dr t.v. radhakrishnan and dr b. k. kulkarni, etc, he did custom synthesis for major multinationals in his career like basf, novartis, sanofi, etc., he has worked in discovery, natural products, bulk drugs, generics, intermediates, fine chemicals, neutraceuticals, gmp, scaleups, etc, he is now helping millions, has 9 million plus hits on google on all organic chemistry websites. his friends call him open superstar worlddrugtracker. his new drug approvals, green chemistry international, all about drugs, eurekamoments, organic spectroscopy international, etc in organic chemistry are some most read blogs he has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 year tenure till date dec 2017, around 35 plus products in his career. he has good knowledge of ipm, gmp, regulatory aspects, he has several international patents published worldwide . he has good proficiency in technology transfer, spectroscopy, stereochemistry, synthesis, polymorphism etc., he suffered a paralytic stroke/ acute transverse mylitis in dec 2007 and is 90 %paralysed, he is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, he has 9 million plus hits on google, 2.5 lakh plus connections on all networking sites, 50 lakh plus views on dozen plus blogs, he makes himself available to all, contact him on +91 9323115463, email [email protected], twitter, @amcrasto , he lives and will die for his family, 90% paralysis cannot kill his soul., notably he has 19 lakh plus views on new drug approvals blog in 216 countries......https://newdrugapprovals.wordpress.com/ , he appreciates the help he gets from one and all, friends, family, glenmark, readers, wellwishers, doctors, drug authorities, his contacts, physiotherapist, etc personal links my sites on the net dr anthony melvin crasto google group organic process development mixxt epernicus scipeople jimdo yolasite my cv slidestaxx wordpress blog about me brandsite skillpages academia.edu diigo wix wix blog issuu scribd biz google blog apnacircle eurekamoments in organic chemistry organic chemistry by dr anthony green chemistry international techno

URL analysis for newdrugapprovals.org

https://newdrugapprovals.org/2018/06/25/bms-986205-ono-7701/
https://newdrugapprovals.org/2015/08/
https://newdrugapprovals.org/2018/07/14/national-award-to-anthony-melvin-crasto-for-contribution-to-pharma-society-from-times-network-for-excellence-in-healthcare-5th-july-2018-taj-lands-end-mumbai-india/comment-page-1/#comment-122044
https://newdrugapprovals.org/2013/07/
https://newdrugapprovals.org/2018/07/14/national-award-to-anthony-melvin-crasto-for-contribution-to-pharma-society-from-times-network-for-excellence-in-healthcare-5th-july-2018-taj-lands-end-mumbai-india/comment-page-1/#comment-122043
https://newdrugapprovals.org/category/us-herbs/
https://newdrugapprovals.org/2018/08/09/fda-approves-treatment-poteligeo-mogamulizumab-kpkc-for-two-rare-types-of-non-hodgkin-lymphoma/?share=google-plus-1
https://newdrugapprovals.org/2018/08/04/anthony-melvin-crasto-gets-international-award-for-outstanding-contribution-to-pharma-society-by-cmo-asia-31st-july-2018-le-meridien-sentosa-singapore/?share=linkedin
https://newdrugapprovals.org/2018/07/31/fda-approves-first-treatment-azedra-iobenguane-i-131-for-rare-adrenal-tumors/
https://newdrugapprovals.org/2018/06/28/alfuzosin-%e5%a1%a9%e9%85%b8%e3%82%a2%e3%83%ab%e3%83%95%e3%82%be%e3%82%b7%e3%83%b3/
https://newdrugapprovals.org/2018/07/31/fda-approves-first-treatment-azedra-iobenguane-i-131-for-rare-adrenal-tumors/?share=pinterest
https://newdrugapprovals.org/2018/04/23/anthony-m-crasto-gets-pharma-excellence-award-at-the-golden-globe-tiger-awards-2018/comment-page-1/#comment-116921
https://newdrugapprovals.org/category/snda-japan/
https://newdrugapprovals.org/2018/06/29/new-ich-guidelines-ich-q13-on-conti-manufacturing-and-ich-q14-on-aqbd/
https://newdrugapprovals.org/2016/04/
ebi.ac.uk
scholar.google.co.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: NEWDRUGAPPROVALS.ORG
Registry Domain ID: D170721006-LROR
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.whois.godaddy.com
Updated Date: 2018-05-05T09:32:20Z
Creation Date: 2014-01-19T04:41:44Z
Registry Expiry Date: 2020-01-19T04:41:44Z
Registrar Registration Expiration Date:
Registrar: Wild West Domains, LLC
Registrar IANA ID: 440
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.4806242505
Reseller:
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Registrant Organization: Domains By Proxy, LLC
Registrant State/Province: Arizona
Registrant Country: US
Name Server: NS1.WORDPRESS.COM
Name Server: NS2.WORDPRESS.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form https://www.icann.org/wicf/)
>>> Last update of WHOIS database: 2018-09-08T22:50:36Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

Access to Public Interest Registry WHOIS information is provided to assist persons in determining the contents of a domain name registration record in the Public Interest Registry registry database. The data in this record is provided by Public Interest Registry for informational purposes only, and Public Interest Registry does not guarantee its accuracy. This service is intended only for query-based access. You agree that you will use this data only for lawful purposes and that, under no circumstances will you use this data to (a) allow, enable, or otherwise support the transmission by e-mail, telephone, or facsimile of mass unsolicited, commercial advertising or solicitations to entities other than the data recipient's own existing customers; or (b) enable high volume, automated, electronic processes that send queries or data to the systems of Registry Operator, a Registrar, or Afilias except as reasonably necessary to register domain names or modify existing registrations. All rights reserved. Public Interest Registry reserves the right to modify these terms at any time. By submitting this query, you agree to abide by this policy.

The Registrar of Record identified in this output may have an RDDS service that can be queried for additional information on how to contact the Registrant, Admin, or Tech contact of the queried domain name.

  REFERRER http://www.pir.org/

  REGISTRAR Public Interest Registry

SERVERS

  SERVER org.whois-servers.net

  ARGS newdrugapprovals.org

  PORT 43

  TYPE domain

DOMAIN

  NAME newdrugapprovals.org

  HANDLE D170721006-LROR

  CREATED 2014-01-19

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientRenewProhibited https://icann.org/epp#clientRenewProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

NSERVER

  NS1.WORDPRESS.COM 198.181.116.9

  NS2.WORDPRESS.COM 198.181.117.9

OWNER

  ORGANIZATION Domains By Proxy, LLC

ADDRESS

  STATE Arizona

  COUNTRY US

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .